These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12919740)

  • 1. Targeted cleavage of hepatitis E virus 3' end RNA mediated by hammerhead ribozymes inhibits viral RNA replication.
    Sriram B; Thakral D; Panda SK
    Virology; 2003 Aug; 312(2):350-8. PubMed ID: 12919740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.
    Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M
    Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes.
    Sakamoto N; Wu CH; Wu GY
    J Clin Invest; 1996 Dec; 98(12):2720-8. PubMed ID: 8981917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cleavage of viral RNA and inhibition of viral translation by hepatitis C virus RNA-specific hammerhead ribozyme in vitro.
    Ohkawa K; Yuki N; Kanazawa Y; Ueda K; Mita E; Sasaki Y; Kasahara A; Hayashi N
    J Hepatol; 1997 Jul; 27(1):78-84. PubMed ID: 9252077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective anti-hepatitis B virus hammerhead ribozymes derived from multimeric precursors.
    Weinberg MS; Ely A; Passman M; Mufamadi SM; Arbuthnot P
    Oligonucleotides; 2007; 17(1):104-12. PubMed ID: 17461767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
    Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
    Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of structure in a long target RNA on ribozyme cleavage efficiency.
    Campbell TB; McDonald CK; Hagen M
    Nucleic Acids Res; 1997 Dec; 25(24):4985-93. PubMed ID: 9396806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo.
    Ramezani A; Joshi S
    Antisense Nucleic Acid Drug Dev; 1996; 6(3):229-35. PubMed ID: 8915508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multitarget ribozyme against the S1 genome segment of reovirus possesses novel cleavage activities and is more efficacious than its constituent mono-ribozymes.
    Shahi S; Banerjea AC
    Antiviral Res; 2002 Jul; 55(1):129-40. PubMed ID: 12076757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
    Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
    Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes.
    Macejak DG; Jensen KL; Jamison SF; Domenico K; Roberts EC; Chaudhary N; von Carlowitz I; Bellon L; Tong MJ; Conrad A; Pavco PA; Blatt LM
    Hepatology; 2000 Mar; 31(3):769-76. PubMed ID: 10706571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A hammerhead ribozyme inhibits the proliferation of an RNA coliphage SP in Escherichia coli.
    Inokuchi Y; Yuyama N; Hirashima A; Nishikawa S; Ohkawa J; Taira K
    J Biol Chem; 1994 Apr; 269(15):11361-6. PubMed ID: 8157667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines.
    Sun LQ; Warrilow D; Wang L; Witherington C; Macpherson J; Symonds G
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9715-9. PubMed ID: 7937878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons.
    Jarczak D; Korf M; Beger C; Manns MP; Krüger M
    FEBS J; 2005 Nov; 272(22):5910-22. PubMed ID: 16279954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repression of hepatitis B virus X gene expression by hammerhead ribozymes.
    Kim YK; Junn E; Park I; Lee Y; Kang C; Ahn JK
    Biochem Biophys Res Commun; 1999 Apr; 257(3):759-65. PubMed ID: 10208856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites.
    Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L
    Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribozymes that cleave an RNA sequence from human immunodeficiency virus: the effect of flanking sequence on rate.
    Goodchild J; Kohli V
    Arch Biochem Biophys; 1991 Feb; 284(2):386-91. PubMed ID: 1989522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activities of HIV-RNA targeted ribozymes transcribed from a 'shot-gun' type ribozyme-trimming plasmid.
    Ohkawa J; Yuyama N; Taira K
    Nucleic Acids Symp Ser; 1992; (27):15-6. PubMed ID: 1289797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.
    Tabler M; Homann M; Tzortzakaki S; Sczakiel G
    Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.